Cas:19740-34-2 2,2-dimethyladamantane manufacturer & supplier

Chemical Name:2,2-dimethyladamantane

CAS.NO:19740-34-2

Synonyms:Tricyclo[3.3.1.13,7]decane,2,2-dimethyl;2,2-Dimethyltricyclo(3.3.1.1(3,7))decane

Molecular Formula:C₁₂H₂₀

Molecular Weight:164.28700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:208.5ºC at 760 mmHg

Density:0.923g/cm3

Index of Refraction:1.491

PSA:

Exact Mass:164.15700

LogP:3.46870

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Tricyclo[3.3.1.13,7]decane,2,2-dimethyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2-Dimethyltricyclo(3.3.1.1(3,7))decane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2-Dimethyltricyclo(3.3.1.1(3,7))decane Use and application,Tricyclo[3.3.1.13,7]decane,2,2-dimethyl technical grade,usp/ep/jp grade.

Related News: The drug, Imfinzi, when added to chemotherapy and the drugmaker��s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said. 2,2-dimethyladamantane manufacturer As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2,2-dimethyladamantane supplier As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2,2-dimethyladamantane vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 2,2-dimethyladamantane factory Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.